Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results and corporate updates announced for quarter ended June 30, 2026.
ZEVRA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results and corporate updates announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
- Conference call and webcast scheduled August 5, 2026 at 4:30 p.m. ET
- Exhibit information not treated as filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Q2 net revenue $39.7M, up 53% YoY, with MIPLYFFA contributing $30.2M and global EAP reimbursements $9.0M
- Net income $8.8M, or $0.14 diluted EPS, versus $74.7M in Q2 2025 distorted by a $148.3M priority-review-voucher gain
- Cash, equivalents and investments $260.2M, supporting strategic execution without near-term capital-markets dependence
- U.S. MIPLYFFA enrollment reached 184 forms since launch, with 69% covered-lives access and Orange Book protection through 2041
- European approval remains unresolved as Zevra seeks re-examination; DiSCOVER enrollment reached 66 patients with three confirmed events
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ZEVRA THERAPEUTICS, INC. 8-K filings
Get the next ZVRA 8-K as it lands
Follow ZVRA for push alerts, or ask the research agent what this filing means.